[{"id":"65969d8a-b172-4873-a916-4494ff06814d","acronym":"IMA401-101","url":"https://clinicaltrials.gov/study/NCT05359445","created_at":"2022-05-03T14:54:12.020Z","updated_at":"2025-02-25T17:37:48.710Z","phase":"Phase 1","brief_title":"IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor","source_id_and_acronym":"NCT05359445 - IMA401-101","lead_sponsor":"Immatics Biotechnologies GmbH","biomarkers":" MAGEA4","pipe":" | ","alterations":" MAGEA4 expression • MAGEA4 overexpression","tags":["MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MAGEA4 expression • MAGEA4 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • IMA401"],"overall_status":"Recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 05/19/2022","start_date":" 05/19/2022","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2025-01-28"}]